GI-Y2 is an orally active, selective Gasdermin D (GSDMD) inhibitor (Kd = 36.0 µM) with anti-pyroptosis activity. GI-Y2 targets GSDMD, impairs membrane anchoring of GSDMD-NT, and blocks GSDMD-dependent lipid binding and pore formation. GI-Y2 suppresses GSDMD-dependent pyroptosis and inflammation, mitigates atherosclerosis and cardiac injury, boosts cell survival, and reduces IL-1beta/IL-18 secretion. GI-Y2 can be used for the research of atherosclerosis and septic myocardial injury[1][2].
Molekulargewicht:
386.38
CAS Nummer:
[1008710-58-4]
Formel:
C18H14N2O6S
Target-Kategorie:
Interleukin Related,Pyroptosis
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
